TDA you can bet your bottom dollar if PAT-SM6 improves Kyprolis in combination they will swoop either the drug or the entire company. Kyprolis is Onyx flagship drug & the main target Amgen was fighting for in its takeover - they are not going to let it slip past if it raises the standing of Kyprolis. Another thing here Onyx / Amgen are trying to get the drug into Europe and what better way than to partner it with SM6 already granted orphan designation by the EMA.
temptation, page-9
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.229M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.5¢ | 0.4¢ | $5.431K | 1.357M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 26519870 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 7889760 | 12 |
View Market Depth
| Last trade - 11.23am 15/11/2024 (20 minute delay) ? |
| PAB (ASX) Chart |